| Literature DB >> 31673381 |
Sheikh Mohammed Shariful Islam1,2,3, Andrew J Farmer4, Kirsten Bobrow4, Ralph Maddison1, Robyn Whittaker5, Leila Anne Pfaeffli Dale5, Andreas Lechner6, Scott Lear7, Zubin Eapen8, Louis Wilhelmus Niessen9, Karla Santo2,3, Sandrine Stepien2, Julie Redfern2,3, Anthony Rodgers10, Clara K Chow2,3.
Abstract
Background: A variety of small mobile phone text-messaging interventions have indicated improvement in risk factors for cardiovascular disease (CVD). Yet the extent of this improvement and whether it impacts multiple risk factors together is uncertain. We aimed to conduct a systematic review and individual patient data (IPD) meta-analysis to investigate the effects of text-messaging interventions for CVD prevention.Entities:
Keywords: cardiovascular diseases; cardiovascular risk factors; diabetes; mHealth; mobile phones; short message service
Year: 2019 PMID: 31673381 PMCID: PMC6802999 DOI: 10.1136/openhrt-2019-001017
Source DB: PubMed Journal: Open Heart ISSN: 2053-3624
Figure 1Study selection process. CENTRAL, Cochrane Central Register of Controlled Trials. CVD, cardiovascular disease; IPD, individual patient data; SMS, short message service.
Characteristics of the study using text message intervention for CVD prevention
| Author, | Sample size | Age (years)* | Intervention versus control | Participant characteristics | Setting, | Primary outcome | Secondary outcome |
| Arora | 128 | 50.7±10.2 | Text messages versus no text message | Patients with poorly controlled diabetes (HbA1c>8%) | Emergency department, | Change in HbA1c | Medication adherence, self-efficacy, performance of self-care tasks, QoL, diabetes-specific knowledge, ED use and patient satisfaction. |
| Bobrow | 1372 | 54.3±11.5 | Usual care versus informational SMS versus interactive SMS | Patients treated for high BP | Single primary care centre in Cape Town, South Africa | Change in mean SBP from baseline to 12 months | Proportion of BP<140/90, medication adherence by PDC and self-report, QoL (EQ5D), clinic attendance and retention, satisfaction with clinic services and care, hospital admissions and basic hypertension knowledge |
| Chow | 710 | 57.9±9.1 | Usual care versus text messaging+usual care | Patients with documented CHD | A large metropolitan tertiary referral public hospital in Sydney, Australia | Change in plasma | Change in SBP, BMI, WC, total cholesterol, HR, smoking status, QoL (SF-12), medication adherence, physical activity, proportion achieving modifiable risk factors, PHQ-9 and nutritional status |
| Islam | 236 | 48.1±9.7 | Routine care versus SMS+routine care | Patients with type 2 diabetes on oral therapy | Tertiary hospital outpatient department, Dhaka, Bangladesh | Mean changes in HbA1c at 6 months | Medication adherence, QoL (EQ5D), physical activity, PHQ-9, BP, WC, BMI and diet |
| Kiselev | 199 | 50±11 | Active ambulatory care management supported by SMS versus traditional ambulatory care management | Patients with arterial hypertension | Ambulatory department of the Saratov Research Institute of Cardiology, | BP levels | BMI and smoking rates |
| Maddison | 171 | 60.2±9.3 | Mobile phone text messages and internet intervention plus usual care, or usual care alone | Adults with a diagnosis of IHD, able to perform exercise and who had access to the internet. | Two metropolitan hospitals in Auckland, New Zealand | Change in maximal oxygen uptake at 6 months | Physical activity (IPAQ), SBP, weight, waist:hip ratio, self-efficacy, QoL (SF-36 and EQ5D) and cost-effectiveness |
| Pfaeffli Dale | 123 | 59.5±11.1 | Centre-based CR (usual care) versus text messages and a supporting website+usual care | Adults diagnosed with CHD | Two large metropolitan hospitals in Auckland, NZ | Proportion of participants adhering to healthy behaviours at 6 months | BP, lipid profile, weight, BMI, waist:hip ratio, self-efficacy, depression and medication adherence |
| Ramachandran | 537 | 46±4.7 | Mobile phone messaging intervention or standard care | Working Indian men aged 35–55 years with BMI of ≥23 kg/m2 with no diabetes or major illness | Public and private-sector industrial units in southeast India | Incidence of type 2 diabetes | BMI, WC, SBP, DBP, lipid profile, total dietary energy intake and physical activity score |
| Wald | 303 | 60 (54–68) | Text group versus no text group | Patients taking BP and/or lipid-lowering medications | 7 Primary care practices in London, UK | Medication use at 6 months, exceeding 80% of the prescribed regimen | Proportion of patients continuing their medications, taking >80% of their prescribed regimen, BP, total cholesterol and LDL |
*Age in years (mean±SD/median (IQR)).
†Studies included in the individual patient data meta-analysis.
BMI, body mass index; BP, blood pressure; CHD, coronary heart disease; CR, cardiac rehabilitation; CVD, cardiovascular disease; DBP, diastolic blood pressure; ED, emergency department; EQ5D, EuroQol Group 5-Dimension Self-report Questionnaire; HbA1c, haemoglobin A1c; IHD, ischaemic heart disease; LDL, low-density lipoprotein; PDC, proportion of days of medication covered; PHQ-9, Patient Health Questionnaire 9; QoL, quality of life; SBP, systolic blood pressure; SF-12, short form 12; SF-36, short form 36; SMS, short message service; StAR, SMS Text-message adherence suppoRt tria; TEXT ME, Effect of Lifestyle-Focused text messaging on risk factor modification in patients with coronary heart disease: a randomized clinical trial; TExT-MED, Trial to examine text message-based mHealth in emergency department patients with diabetes; WC, waist circumference.
Figure 2Standard meta-analysis at end follow-up on systolic blood pressure results (random-effects model). MPID, mobile phone intervention for diabetes; WMD, weighted mean difference.
Trials included in the individual patient data meta-analysis with outcomes by trial at the end of follow-up*
| Trial | Location | Participants | Outcome | n | Intervention | Control | Mean difference (95% CI) | P value for the difference |
| Systolic blood pressure (mm Hg) at end of follow-up | ||||||||
| HEART | New Zealand | IHD | Number of observations | 152 | 74 | 78 | ||
| Analysis of covariance | 135.7 (132.7 to 138.6) | 131.1 (128.3 to 134.0) | 4.6 (0.5 to 8.7) | 0.0289 | ||||
| MPID | Bangladesh | Diabetes | Number of observations | 236 | 118 | 118 | ||
| Analysis of covariance | 127.1 (124.8 to 129.4) | 126.7 (124.4 to 129.0) | 0.4 (−2.8 to 3.7) | 0.7968 | ||||
| StAR | South Africa | Hypertension | Number of observations | 802 | 406 | 396 | ||
| Analysis of covariance | 133.2 (131.7 to 134.8) | 135.4 (133.8 to 136.9) | −2.1 (−4.3 to 0.1) | 0.0599 | ||||
| Text4Heart | New Zealand | CHD | Number of observations | 114 | 56 | 58 | ||
| Analysis of covariance | 135.5 (130.9 to 140.1) | 135.4 (130.8 to 139.9) | 0.1 (−6.4 to 6.6) | 0.9800 | ||||
| TEXT ME | Australia | CHD | Number of observations | 672 | 329 | 343 | ||
| Analysis of covariance | 128.2 (126.7 to 129.8) | 135.8 (134.3 to 137.3) | −7.6 (−9.8 to −5.4) | <0.0001 | ||||
| Diastolic blood pressure (mm Hg) at the end of follow-up | ||||||||
| HEART | New Zealand | IHD | Number of observations | 152 | 74 | 78 | ||
| Analysis of covariance | 79.3 (77.4 to 81.3) | 77.7 (75.8 to 79.6) | 1.6 (−1.1 to 4.4) | 0.2483 | ||||
| MPID | Bangladesh | Diabetes | Number of observations | 236 | 118 | 118 | ||
| Analysis of covariance | 79.1 (77.9 to 80.4) | 78.2 (76.9 to 79.4) | 1.0 (−0.8 to 2.8) | 0.2844 | ||||
| StAR | South Africa | Hypertension | Number of observations | 802 | 406 | 396 | ||
| Analysis of covariance | 82.9 (81.9 to 84.0) | 84.0 (83.0 to 85.1) | −1.1 (−2.6 to 0.4) | 0.1497 | ||||
| Text4Heart | New Zealand | CHD | Number of observations | 114 | 56 | 58 | ||
| Analysis of covariance | 79.4 (76.8 to 82.0) | 79.6 (77.1 to 82.1) | −0.2 (−3.8 to 3.4) | 0.9019 | ||||
| TEXT ME | Australia | CHD | Number of observations | 673 | 329 | 344 | ||
| Analysis of covariance | 80.5 (79.6 to 81.5) | 83.6 (82.7 to 84.5) | −3.1 (−4.4 to −1.7) | <0.0001 | ||||
| BMI (kg/m2) at the end of follow-up | ||||||||
| HEART | New Zealand | IHD | Number of observations | 152 | 74 | 78 | ||
| Analysis of covariance | 28.7 (28.4 to 28.9) | 28.5 (28.2 to 28.7) | 0.2 (−0.1 to 0.5) | 0.2569 | ||||
| MPID | Bangladesh | Diabetes | Number of observations | 163 | 90 | 73 | ||
| Analysis of covariance | 26.5 (25.9 to 27.1) | 26.0 (25.4 to 26.7) | 0.4 (−0.5 to 1.3) | 0.3425 | ||||
| StAR | South Africa | Hypertension | Number of observations | 795 | 401 | 394 | ||
| Analysis of covariance | 33.5 (33.3 to 33.7) | 33.7 (33.5 to 33.9) | −0.1 (−0.4 to 0.2) | 0.3732 | ||||
| Text4Heart | New Zealand | CHD | Number of observations | 113 | 55 | 58 | ||
| Analysis of covariance | 29.1 (28.8 to 29.4) | 29.2 (28.9 to 29.5) | −0.1 (−0.6 to 0.3) | 0.6015 | ||||
| TEXT ME | Australia | CHD | Number of observations | 684 | 335 | 349 | ||
| Analysis of covariance | 29.0 (28.8 to 29.3) | 30.3 (30.1 to 30.5) | −1.3 (−1.6 to −0.9) | <0.0001 | ||||
Note: All randomised patients with both visits assessed at baseline and at the end of follow-up have been included in this analysis.
End of follow-up corresponds to month 12 for StAR study and month 6 for other studies.
Primary analysis—non-adjusted model: analysis of covariance including randomised treatment and baseline value.
n is the total number of observations used (available) for the analysis at month 6 using baseline value as covariate.
CHD, coronary heart disease; IHD, ischaemic heart disease; MPID, mobile phone intervention for diabetes; StAR, Mobile Phone Text Messages to Support Treatment Adherence in Adults With High Blood Pressure (SMS-Text Adherence Support); TEXT ME, Effect of Lifestyle-Focused text messaging on risk factor modification in patients with coronary heart disease; TExT-MED, Trial to examine text message-based mHealth in emergency department patients with diabetes.
Individual patient data meta-analysis at the end of follow-up*
| Outcome | Model | Intervention | Control | Mean difference | P value for the difference |
| SBP | Random-effects model (1a) | 132.1 (128.7 to 135.5) | 133.4 (130.0 to 136.8) | −1.3 (−5.4 to 2.7) | 0.5236 |
| Fixed-effects model (2) | 131.3 (130.2 to 132.4) | 134.3 (133.2 to 135.4) | −3.1 (−4.4 to −1.7) | <0.0001 | |
| DBP | Random-effects model (1a) | 80.9 (79.4 to 82.4) | 81.7 (80.2 to 83.2) | −0.8 (−2.5 to 1.0) | 0.3912 |
| Fixed-effects model (2) | 80.6 (79.8 to 81.3) | 81.9 (81.2 to 82.6) | −1.3 (−2.2 to −0.5) | 0.0018 | |
| BMI | Random-effects model (1b) | 30.6 (30.2 to 31.1) | 30.8 (30.4 to 31.3) | −0.2 (−0.8 to 0.4) | 0.5200 |
| Fixed-effects model (2) | 30.5 (30.3 to 30.7) | 31.0 (30.8 to 31.1) | −0.5 (−0.7 to −0.3) | <0.0001 |
Note: All randomised patients with both visits assessed at baseline and at month 6 have been included in this analysis.
Primary analysis—analysis of covariance, including randomised treatment and baseline value as fixed effect: model 1: (a) includes trial random effect and random treatment by trial interaction, (b) includes trial fixed effect and random treatment by trial interaction when model 1a estimates trial random effect to zero; model 2: only fixed effects, including trial effect; model 3: sensitivity analysis pooling the estimates from the five trials using a standard meta-analysis checking for data heterogeneity between trials.
*For the StAR study, 12 month data was used for follow-up. For all other studies, 6 month data was used for follow-up.
BMI, body mass index; DBP, diastolic blood pressure; SBP, systolic blood pressure.